₹4.5*
MRP ₹5
10% off
₹4.25*
MRP ₹5
15% CB
₹0.75 cashback(15%)
Free Delivery
With Circle membership
(Inclusive of all Taxes)
This offer price is valid on orders above ₹800. Apply coupon PHARMA10/PHARMA18 (excluding restricted items)
Prescription drugWhats That
Composition
GENTAMICIN-20MG
Consume Type
PARENTERAL
Return Policy
3 Days Returnable
Expires on or after
Apr-24
for this medicine
Drug-Drug Interactions
GentamicinIopamidol
Severe
GentamicinTenofovir alafenamide
Severe
Drug-Drug Interactions
Login/Sign Up
GentamicinIopamidol
Severe
How does the drug interact with Genticyn 20 mg Injection 2 ml:
Co-administration of Iopamidol with Genticyn 20 mg Injection 2 ml may increase the risk of kidney problems.
How to manage the interaction:
Co-administration of Genticyn 20 mg Injection 2 ml with Iopamidol can possibly result in an interaction, but it can be taken if a doctor has advised it. It's important to keep an eye on how much you pee. If you notice any changes, like peeing more or less than usual, it's a good idea to let your doctor know right away. These changes could be a sign of problems with your kidneys, diabetes, or other health issues. Other symptoms to watch out for include feeling sick, throwing up, not wanting to eat, gaining or losing weight suddenly, or having trouble breathing. Do not stop using any medications without a doctor's advice.
Co-administration of Iopamidol with Genticyn 20 mg Injection 2 ml may increase the risk of kidney problems.
How to manage the interaction:
Co-administration of Genticyn 20 mg Injection 2 ml with Iopamidol can possibly result in an interaction, but it can be taken if a doctor has advised it. It's important to keep an eye on how much you pee. If you notice any changes, like peeing more or less than usual, it's a good idea to let your doctor know right away. These changes could be a sign of problems with your kidneys, diabetes, or other health issues. Other symptoms to watch out for include feeling sick, throwing up, not wanting to eat, gaining or losing weight suddenly, or having trouble breathing. Do not stop using any medications without a doctor's advice.
GentamicinTenofovir alafenamide
Severe
How does the drug interact with Genticyn 20 mg Injection 2 ml:
Co-administration of Tenofovir alafenamide may cause kidney problems and combining it Genticyn 20 mg Injection 2 ml may increase that risk.
How to manage the interaction:
Although there is a possible interaction, Genticyn 20 mg Injection 2 ml can be taken with tenofovir alafenamide if prescribed by the doctor. Consult the doctor if you experience signs and symptoms of kidney damage such as nausea, vomiting, loss of appetite, increased or decreased urination, sudden weight gain or weight loss, fluid retention, swelling, shortness of breath, bone pain, muscle cramps, tiredness, weakness, dizziness, confusion, and irregular heart rhythm. Do not stop using any medications without consulting a doctor.
Co-administration of Tenofovir alafenamide may cause kidney problems and combining it Genticyn 20 mg Injection 2 ml may increase that risk.
How to manage the interaction:
Although there is a possible interaction, Genticyn 20 mg Injection 2 ml can be taken with tenofovir alafenamide if prescribed by the doctor. Consult the doctor if you experience signs and symptoms of kidney damage such as nausea, vomiting, loss of appetite, increased or decreased urination, sudden weight gain or weight loss, fluid retention, swelling, shortness of breath, bone pain, muscle cramps, tiredness, weakness, dizziness, confusion, and irregular heart rhythm. Do not stop using any medications without consulting a doctor.
GentamicinDoxacurium chloride
Severe
How does the drug interact with Genticyn 20 mg Injection 2 ml:
Co-administration of Doxacurium with Genticyn 20 mg Injection 2 ml may increase the risk of side effects.
How to manage the interaction:
There may be a possibility of interaction between Genticyn 20 mg Injection 2 ml and Doxacurium chloride, but it can be taken if prescribed by a doctor. If you have trouble breathing or feel like you can't breathe at all, it's important to contact a doctor right away. This is especially true if you're having difficulty breathing for a long time. Do not discontinue any medications without consulting a doctor.
Co-administration of Doxacurium with Genticyn 20 mg Injection 2 ml may increase the risk of side effects.
How to manage the interaction:
There may be a possibility of interaction between Genticyn 20 mg Injection 2 ml and Doxacurium chloride, but it can be taken if prescribed by a doctor. If you have trouble breathing or feel like you can't breathe at all, it's important to contact a doctor right away. This is especially true if you're having difficulty breathing for a long time. Do not discontinue any medications without consulting a doctor.
GentamicinPipecuronium bromide
Severe
How does the drug interact with Genticyn 20 mg Injection 2 ml:
Co-administration of Pipecuronium bromide with Genticyn 20 mg Injection 2 ml may increase the risk or severity of side effects.
How to manage the interaction:
There may be a possibility of interaction between Genticyn 20 mg Injection 2 ml and Pipecuronium bromide, but it can be taken if prescribed by a doctor. If you have trouble breathing or feel like you can't breathe at all, it's important to contact your doctor right away. This is especially true if you're having difficulty breathing for a long time. Do not stop using any medications without a doctor's advice.
Co-administration of Pipecuronium bromide with Genticyn 20 mg Injection 2 ml may increase the risk or severity of side effects.
How to manage the interaction:
There may be a possibility of interaction between Genticyn 20 mg Injection 2 ml and Pipecuronium bromide, but it can be taken if prescribed by a doctor. If you have trouble breathing or feel like you can't breathe at all, it's important to contact your doctor right away. This is especially true if you're having difficulty breathing for a long time. Do not stop using any medications without a doctor's advice.
GentamicinVecuronium
Severe
How does the drug interact with Genticyn 20 mg Injection 2 ml:
Co-administration of Vecuronium with Genticyn 20 mg Injection 2 ml can make the treatment more effective.
How to manage the interaction:
Taking Vecuronium with Genticyn 20 mg Injection 2 ml together can possibly result in an interaction, but it can be taken if a doctor has advised it. If you have any of these symptoms - having trouble breathing or feeling like you can't catch your breath for a long time - it's important to call a doctor right away. Do not stop using any medications without a doctor's advice.
Co-administration of Vecuronium with Genticyn 20 mg Injection 2 ml can make the treatment more effective.
How to manage the interaction:
Taking Vecuronium with Genticyn 20 mg Injection 2 ml together can possibly result in an interaction, but it can be taken if a doctor has advised it. If you have any of these symptoms - having trouble breathing or feeling like you can't catch your breath for a long time - it's important to call a doctor right away. Do not stop using any medications without a doctor's advice.
GentamicinTemsirolimus
Severe
How does the drug interact with Genticyn 20 mg Injection 2 ml:
Co-administration of Genticyn 20 mg Injection 2 ml and Temsirolimus may increase the risk of kidney problems.
How to manage the interaction:
Co-administration of Genticyn 20 mg Injection 2 ml with Temsirolimus can possibly result in an interaction, but it can be taken if a doctor has advised it. It's important to keep an eye on how much you pee. If you notice any changes like peeing more or less than usual, it's a good idea to let your doctor know right away. Some signs to watch out for include gaining weight quickly, feeling bloated, having trouble breathing, or feeling sick to your stomach. Other symptoms to be aware of are not feeling hungry, losing weight, swelling, muscle cramps, feeling weak or dizzy, feeling confused, or having an irregular heartbeat. Do not stop using any medications without a doctor's advice.
Co-administration of Genticyn 20 mg Injection 2 ml and Temsirolimus may increase the risk of kidney problems.
How to manage the interaction:
Co-administration of Genticyn 20 mg Injection 2 ml with Temsirolimus can possibly result in an interaction, but it can be taken if a doctor has advised it. It's important to keep an eye on how much you pee. If you notice any changes like peeing more or less than usual, it's a good idea to let your doctor know right away. Some signs to watch out for include gaining weight quickly, feeling bloated, having trouble breathing, or feeling sick to your stomach. Other symptoms to be aware of are not feeling hungry, losing weight, swelling, muscle cramps, feeling weak or dizzy, feeling confused, or having an irregular heartbeat. Do not stop using any medications without a doctor's advice.
GentamicinRocuronium bromide
Severe
How does the drug interact with Genticyn 20 mg Injection 2 ml:
When Rocuronium is used with Genticyn 20 mg Injection 2 ml, it can make the treatment more effective.
How to manage the interaction:
Co-administration of Rocuronium bromide with Genticyn 20 mg Injection 2 ml can possibly result in an interaction, but it can be taken if a doctor has advised it. Do not discontinue any medications without consulting a doctor.
When Rocuronium is used with Genticyn 20 mg Injection 2 ml, it can make the treatment more effective.
How to manage the interaction:
Co-administration of Rocuronium bromide with Genticyn 20 mg Injection 2 ml can possibly result in an interaction, but it can be taken if a doctor has advised it. Do not discontinue any medications without consulting a doctor.
GentamicinBotulinum toxin
Severe
How does the drug interact with Genticyn 20 mg Injection 2 ml:
Using Genticyn 20 mg Injection 2 ml with Botulinum toxin can increase the risk of side effects.
How to manage the interaction:
Although there is an interaction between Botulinum toxin and Genticyn 20 mg Injection 2 ml, they can be taken together if prescribed by a doctor. However, contact a doctor immediately if you experience muscle weakness or trouble breathing, swallowing, or speaking. Do not discontinue any medications without consulting a doctor.
Using Genticyn 20 mg Injection 2 ml with Botulinum toxin can increase the risk of side effects.
How to manage the interaction:
Although there is an interaction between Botulinum toxin and Genticyn 20 mg Injection 2 ml, they can be taken together if prescribed by a doctor. However, contact a doctor immediately if you experience muscle weakness or trouble breathing, swallowing, or speaking. Do not discontinue any medications without consulting a doctor.
GentamicinFoscarnet
Severe
How does the drug interact with Genticyn 20 mg Injection 2 ml:
Co-administration of Genticyn 20 mg Injection 2 ml with Foscarnet can increase the risk of kidney damage.
How to manage the interaction:
Although taking Genticyn 20 mg Injection 2 ml and Foscarnet together can evidently cause an interaction, it can be taken if a doctor has suggested it. If you have any of these symptoms, it's important to contact your doctor right away: seizures, an irregular heart rhythm, feeling sick, swelling, sudden weight gain or loss, severe pain in your upper stomach, strong heartbeats, feeling dizzy, or chest pain. Do not stop using any medications without a doctor's advice.
Co-administration of Genticyn 20 mg Injection 2 ml with Foscarnet can increase the risk of kidney damage.
How to manage the interaction:
Although taking Genticyn 20 mg Injection 2 ml and Foscarnet together can evidently cause an interaction, it can be taken if a doctor has suggested it. If you have any of these symptoms, it's important to contact your doctor right away: seizures, an irregular heart rhythm, feeling sick, swelling, sudden weight gain or loss, severe pain in your upper stomach, strong heartbeats, feeling dizzy, or chest pain. Do not stop using any medications without a doctor's advice.
GentamicinSirolimus
Severe
How does the drug interact with Genticyn 20 mg Injection 2 ml:
Coadministration of Sirolimus with Genticyn 20 mg Injection 2 ml may increase the risk or severity of kidney problems.
How to manage the interaction:
Although there is a possible interaction, Genticyn 20 mg Injection 2 ml can be taken with sirolimus if prescribed by the doctor. Consult the doctor if you experience symptoms of kidney damage such as nausea, vomiting, loss of appetite, increased or decreased urination, sudden weight gain or weight loss, swelling, shortness of breath, muscle cramps, tiredness, weakness, dizziness, confusion, and irregular heart rhythm. Do not stop using any medication without consulting your doctor.
Coadministration of Sirolimus with Genticyn 20 mg Injection 2 ml may increase the risk or severity of kidney problems.
How to manage the interaction:
Although there is a possible interaction, Genticyn 20 mg Injection 2 ml can be taken with sirolimus if prescribed by the doctor. Consult the doctor if you experience symptoms of kidney damage such as nausea, vomiting, loss of appetite, increased or decreased urination, sudden weight gain or weight loss, swelling, shortness of breath, muscle cramps, tiredness, weakness, dizziness, confusion, and irregular heart rhythm. Do not stop using any medication without consulting your doctor.
Drug-Food Interactions
No Drug - Food interactions found in our database. Some may be unknown. Consult your doctor for what to avoid during medication.
Drug-Food Interactions
Login/Sign Up
Drug-Diseases Interactions
GENTAMICIN-20MGOther symptoms and signs involving the digestive system and abdomen
Severe
GENTAMICIN-20MGMyasthenia gravis and other myoneural disorders
Severe
Drug-Diseases Interactions
Login/Sign Up
GENTAMICIN-20MGOther symptoms and signs involving the digestive system and abdomen
Severe
How does the disease interact with Genticyn 20 mg Injection 2 ml:
Adequate hydration is critical for reducing the risk of oto- and nephrotoxicity associated with aminoglycoside usage. Dehydration should preferably be treated before starting therapy. Fluid status should be continuously maintained in patients who are at risk of dehydration, such as those who have severe and/or prolonged diarrhoea or vomiting. If indications of renal irritation appear during therapy, hydration should be increased as directed, followed by a dose reduction if necessary. If urine flow gradually decreases or azotemia worsens, therapy should be discontinued.
How to manage the interaction:
Dehydration should be corrected prior to initiation of therapy. Fluid status should be monitored closely in patients who may be at risk for dehydration, such as those with severe and/or prolonged diarrhea or vomiting. Therapy should be withdrawn if urinary output decreases progressively or azotemia (elevated levels of urea) increases.
Adequate hydration is critical for reducing the risk of oto- and nephrotoxicity associated with aminoglycoside usage. Dehydration should preferably be treated before starting therapy. Fluid status should be continuously maintained in patients who are at risk of dehydration, such as those who have severe and/or prolonged diarrhoea or vomiting. If indications of renal irritation appear during therapy, hydration should be increased as directed, followed by a dose reduction if necessary. If urine flow gradually decreases or azotemia worsens, therapy should be discontinued.
How to manage the interaction:
Dehydration should be corrected prior to initiation of therapy. Fluid status should be monitored closely in patients who may be at risk for dehydration, such as those with severe and/or prolonged diarrhea or vomiting. Therapy should be withdrawn if urinary output decreases progressively or azotemia (elevated levels of urea) increases.
GENTAMICIN-20MGMyasthenia gravis and other myoneural disorders
Severe
How does the disease interact with Genticyn 20 mg Injection 2 ml:
Aminoglycosides can elicit dose-related neuromuscular blockade and muscle weakness, especially in patients with neuromuscular illness or hypocalcemia, as well as in those undergoing general anaesthesia, neuromuscular blocking medications, or substantial transfusions of citrate-anticoagulated blood. Although neuromuscular blockade caused by aminoglycosides is usually self-limiting, it can occasionally result in respiratory paralysis. The most potent neuromuscular blocking drug in the class is regarded to be neomycin. However, the risk is greatest with large dosages instilled intraperitoneally or intrapleurally, or with fast intravenous administration of parenteral aminoglycosides. In patients with neuromuscular problems (e.g., myasthenia gravis, parkinsonian syndrome, botulism) or hypocalcemia, aminoglycoside therapy should be used with caution. If indications of respiratory paralysis appear during aminoglycoside therapy, the medicine should be stopped and, if necessary, mechanical breathing assistance administered.
How to manage the interaction:
Therapy should be administered cautiously in patients with neuromuscular disorders (e.g., myasthenia gravis, Parkinsonian syndrome, botulism) or hypocalcemia (low calcium levels). The drug should be discontinued and mechanical respiratory assistance provided if needed if signs of respiratory paralysis occur during therapy.
Aminoglycosides can elicit dose-related neuromuscular blockade and muscle weakness, especially in patients with neuromuscular illness or hypocalcemia, as well as in those undergoing general anaesthesia, neuromuscular blocking medications, or substantial transfusions of citrate-anticoagulated blood. Although neuromuscular blockade caused by aminoglycosides is usually self-limiting, it can occasionally result in respiratory paralysis. The most potent neuromuscular blocking drug in the class is regarded to be neomycin. However, the risk is greatest with large dosages instilled intraperitoneally or intrapleurally, or with fast intravenous administration of parenteral aminoglycosides. In patients with neuromuscular problems (e.g., myasthenia gravis, parkinsonian syndrome, botulism) or hypocalcemia, aminoglycoside therapy should be used with caution. If indications of respiratory paralysis appear during aminoglycoside therapy, the medicine should be stopped and, if necessary, mechanical breathing assistance administered.
How to manage the interaction:
Therapy should be administered cautiously in patients with neuromuscular disorders (e.g., myasthenia gravis, Parkinsonian syndrome, botulism) or hypocalcemia (low calcium levels). The drug should be discontinued and mechanical respiratory assistance provided if needed if signs of respiratory paralysis occur during therapy.
GENTAMICIN-20MGOther disorders of ear, not elsewhere classified
Severe
How does the disease interact with Genticyn 20 mg Injection 2 ml:
Aminoglycosides can harm the eighth cranial nerve, causing vestibular and/or auditory toxicity. Dizziness, nystagmus, vertigo, ataxia, tinnitus, and varied degrees of hearing impairment are among the symptoms. Following the discontinuation of the medicine, permanent hearing loss, including whole or partial irreversible bilateral deafness, may occur. Therapy with aminoglycosides, especially if extended (> 10 days), should be used with caution in patients with preexisting vestibular and/or auditory impairment, as it may delay or obfuscate the diagnosis of a drug-induced ototoxic impact. Patients should be adequately hydrated, the usual aminoglycoside dosage should not be exceeded, use with other ototoxic agents should be avoided, and peak and trough serum aminoglycoside concentrations should be determined on a regular basis and dosage adjusted to maintain desired levels.
How to manage the interaction:
Therapy should be administered with caution in patients with ototoxicity. The dosage should be reduced or therapy shoule be withdrawn if signs and symptoms of toxicity develop.
Aminoglycosides can harm the eighth cranial nerve, causing vestibular and/or auditory toxicity. Dizziness, nystagmus, vertigo, ataxia, tinnitus, and varied degrees of hearing impairment are among the symptoms. Following the discontinuation of the medicine, permanent hearing loss, including whole or partial irreversible bilateral deafness, may occur. Therapy with aminoglycosides, especially if extended (> 10 days), should be used with caution in patients with preexisting vestibular and/or auditory impairment, as it may delay or obfuscate the diagnosis of a drug-induced ototoxic impact. Patients should be adequately hydrated, the usual aminoglycoside dosage should not be exceeded, use with other ototoxic agents should be avoided, and peak and trough serum aminoglycoside concentrations should be determined on a regular basis and dosage adjusted to maintain desired levels.
How to manage the interaction:
Therapy should be administered with caution in patients with ototoxicity. The dosage should be reduced or therapy shoule be withdrawn if signs and symptoms of toxicity develop.
GENTAMICIN-20MGUnspecified kidney failure
Severe
How does the disease interact with Genticyn 20 mg Injection 2 ml:
Aminoglycosides have the potential to be ototoxic and nephrotoxic. Damage to the eighth cranial nerve can cause vestibular and/or auditory toxicities such as dizziness, nystagmus, vertigo, ataxia, tinnitus, and varied degrees of hearing impairment. Tubular necrosis, increases in BUN, nonprotein nitrogen, and serum creatinine concentration, decreases in urine specific gravity and creatinine clearance, proteinuria, and cells or casts in the urine are all signs of nephrotoxicity. Rarely, renal electrolyte wasting can cause hypocalcemia, hypomagnesemia, and hypokalemia, which can be accompanied with paresthesia, tetany, disorientation, and positive Chvostek and Trousseau symptoms. Although aminoglycoside-induced nephrotoxicity is often reversible after treatment withdrawal, mortality from uremia has happened on rare occasions. Patients with renal impairment should be treated with caution and at lower doses of aminoglycosides, as they may be at risk.Drug buildup increases the risk of oto- and nephrotoxicity. Patients should be adequately hydrated, the usual aminoglycoside dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and peak and trough serum aminoglycoside concentrations should be determined on a regular basis and dosage adjusted to maintain desired levels. If toxicity develops, renal and eighth cranial nerve function should be constantly monitored, and the dosage lowered or therapy discontinued.
How to manage the interaction:
Therapy should be administered cautiously at reduced dosages in patients with kidney impairment. Patients should be adequately hydrated, the dose should not be exceeded, and use with other neuro- and nephrotoxic agents should be avoided to minimize the risk of toxicity.
Aminoglycosides have the potential to be ototoxic and nephrotoxic. Damage to the eighth cranial nerve can cause vestibular and/or auditory toxicities such as dizziness, nystagmus, vertigo, ataxia, tinnitus, and varied degrees of hearing impairment. Tubular necrosis, increases in BUN, nonprotein nitrogen, and serum creatinine concentration, decreases in urine specific gravity and creatinine clearance, proteinuria, and cells or casts in the urine are all signs of nephrotoxicity. Rarely, renal electrolyte wasting can cause hypocalcemia, hypomagnesemia, and hypokalemia, which can be accompanied with paresthesia, tetany, disorientation, and positive Chvostek and Trousseau symptoms. Although aminoglycoside-induced nephrotoxicity is often reversible after treatment withdrawal, mortality from uremia has happened on rare occasions. Patients with renal impairment should be treated with caution and at lower doses of aminoglycosides, as they may be at risk.Drug buildup increases the risk of oto- and nephrotoxicity. Patients should be adequately hydrated, the usual aminoglycoside dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and peak and trough serum aminoglycoside concentrations should be determined on a regular basis and dosage adjusted to maintain desired levels. If toxicity develops, renal and eighth cranial nerve function should be constantly monitored, and the dosage lowered or therapy discontinued.
How to manage the interaction:
Therapy should be administered cautiously at reduced dosages in patients with kidney impairment. Patients should be adequately hydrated, the dose should not be exceeded, and use with other neuro- and nephrotoxic agents should be avoided to minimize the risk of toxicity.
Author Details
